Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 9038 results

  1. Transcranial direct current stimulation (tDCS) for the treatment of refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Dronabinol for treating muscle spasticity in multiple sclerosis after 2 treatments [TSID10638]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. BioTime's Premvia HyStem hydrogel for the management of a wide range of wounds

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Remedē System (Respicardia Inc) for transvenous stimulation of the phrenic nerve towards the tehrapy of Central sleep apnoea - moderate to severe

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Full Endoscopic Spine Surgery

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation